Physicians' Academy for Cardiovascular Education

Addition of novel agent to metformin to treat overweight type 2 diabetes did not meet efficacy endpoint

News - June 30, 2015

Results of treatment of overweight type 2 diabetic patients with the potential first-in-class 11β-hydroxysteroid dehydrogenase type 1 (11β HSD1) inhibitor BI187004/VTP-34072, in addition to metformin in an ongoing phase 2 proof-of-concept clinical trial, have been presented.
BI187004/VTP-34072 is an 11β HSD1 inhibitor that is being studied for the treatment of type 2 diabetes and metabolic syndrome. In preclinical studies, BI187004/VTP-34072 had a positive impact on multiple cardiovascular and metabolic risk factors associated with metabolic syndrome, which differentiates it from other classes of type 2 diabetes drugs. BI187004/VTP-34072 is currently being studied in an ongoing Phase 2 proof-of-concept trial assessing efficacy and tolerability in diabetic patients on stable doses of metformin and as monotherapy.

Safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BI187004/VTP-34072 as monotherapy or as an add-on to metformin background therapy are being investigated over 28 days in a randomised, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Primary efficacy data (fasting plasma glucose) from the metformin arm did not meet predefined endpoint criteria. Data from the placebo-controlled monotherapy arm of the trial, which is still ongoing, are expected to be reported later this year.
 

Source

Press release Vitae Pharmaceuticals, June 29, 2015

Share this page with your colleagues and friends: